Search results
Results from the WOW.Com Content Network
Radionuclide angiography is an area of nuclear medicine which specialises in imaging to show the functionality of the right and left ventricles of the heart, thus allowing informed diagnostic intervention in heart failure. It involves use of a radiopharmaceutical, injected into a patient, and a gamma camera for acquisition.
Radionuclide therapy can be used to treat conditions such as hyperthyroidism, thyroid cancer, skin cancer and blood disorders. In nuclear medicine therapy, the radiation treatment dose is administered internally (e.g. intravenous or oral routes) or externally direct above the area to treat in form of a compound (e.g. in case of skin cancer).
Cardiac ventriculography involves injecting contrast media into the heart's ventricle(s) to measure the volume of blood pumped. Cardiac ventriculography can be performed with a radionuclide in radionuclide ventriculography or with an iodine-based contrast in cardiac chamber catheterization.
Radionuclide scanning of the scrotum is the most accurate imaging technique to diagnose testicular torsion, but it is not routinely available. [16] The agent of choice for this purpose is technetium-99m pertechnetate. [17] Initially it provides a radionuclide angiogram, followed by a static image after the radionuclide has perfused the tissue.
A 2009 study indicated that for every 100,000 people screened with CAC testing every 5 years between ages 45 to 75 years (men) or 55 to 75 years (women), there would be 42 (men) or 62 (women) additional radiation induced cancer cases. [13]
For men over 64 with prostate cancer limited to the pelvis, using fewer, larger doses of radiation (hypofractionation) results in similar overall survival rates. [28] The risk of dying from prostate cancer or having acute bladder side effects may be similar to that of longer radiation treatment. [ 28 ]
Myocardial perfusion imaging or scanning (also referred to as MPI or MPS) is a nuclear medicine procedure that illustrates the function of the heart muscle (). [1]It evaluates many heart conditions, such as coronary artery disease (CAD), [2] hypertrophic cardiomyopathy and heart wall motion abnormalities.
The prevalence of AAA worldwide in 2019 was about 0.9% in people under age 79 years, [4] whereas a 2014 review reported a range of 2-12%, occurring in about 8% of men more than 65 years of age. [13] Men are about four times more likely to have AA compared to women at any age, with death occurring in about 55-64% of people having AAA rupture.